Business Wire

PV-INFOLINK

Share
2019 Trends to Watch in PV Market: High-efficiency Module

Upon the return of SNEC PV Power Expo next month, PV InfoLink will explore the PV product trends and the transition of module output at a seminar held in Shanghai on June 3.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190527005064/en/

Titled “2H19 PV Market Outlook and Forecast,” the seminar will feature topics spanning China’s transition to subsidy-free market , PV market outlook and supply chain. PV InfoLink, a leading solar market research firm and host of the seminar, has invited top-tier companies including Jinko, Longi, and GCL-Si to discuss the major issues.

As the global PV market grows continuously, China’s module exports had hit a record high of 16 GW in Q1’19, a significant growth from last Q4’s 12 GW. In addition to India and Japan’s traditional high season, China exported 5 GW of modules to the European markets in Q1.

Following the release of Chinese PV policies, market demand is expected to heat up in July. Thus, PV InfoLink projected that the global demand this year will amount to 123 GW, a 25% growth from last year.

SE-PERC modules have become a norm for high-efficiency, however, it’s getting more difficult to make new breakthrough on cell side, therefore, it requires module technologies and larger wafers to achieve higher module power output. According to China customs data, total exports of special solar modules paired with module technologies had exceeded 2GW in Q1, surpassing the cumulative volume of special modules last year.

So far, special modules accounted for 17% of total Chinese module exports. Among them, half-cut module is by far the most mature technology. Australia, the Netherlands, and Japan are the top trading partners of China in terms of half-cut modules, having imported mostly 60-cell 315-320W and 72-cell 370-375W modules.

Shingled modules have higher output than others. However, exporting shingled modules is rather restricted due to patent protection. So far, China exported only 253 MW of 60-cell 320-330W and 72-cell 395-400W modules to Australia and Asian countries in Q1.

This year also saw the emergence of panels consisting of more cells, which can push up 78-cell modules’ output to 400 W.

Overall, the module output has improved significantly this year. 60-cell P-type module output can achieve 315W-320W through using larger wafers or half-cut cells. After the use of larger wafers becomes more common in the second half, some of the P-type modules could achieve 325-330W of output, and that will put N-type modules under pressure because of its lower cost-performance.

Vikram Solar, a Tier 1 solar module manufacturer and EPC solutions provider that has played an important role in shaping PV revolution, is a golden sponsor of the event.

PV InfoLink provides the most up-to-date market information and accurate price quotes across the supply chain, which is referenced by most large companies for price negotiation to stay competitive in the market. Details on how to attend the seminar can be found through the event page here .

Contact:

PV InfoLink Ellie Lee service@pvinfolink.com +886 227163123

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society

Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release

- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and

Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release

The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p

Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release

‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye